INVESTOR RELATIONS
press release – price-sensitive
SALES AS OF SEPTEMBER 30, 2024 AMOUNTS TO APPROXIMATELY 2.8 MILLION EUROS
SALES AS OF SEPTEMBER 30, 2024 AMOUNTS TO APPROXIMATELY 2.8 MILLION EUROSTHE BOARD OF DIRECTORS HAS APPROVED THE HALF-YEARLY REPORT AS OF 30 JUNE 2024
THE BOARD OF DIRECTORS HAS APPROVED THE HALF-YEARLY REPORT AS OF 30 JUNE 2024JOINT VENTURE AGREEMENT SIGNED WITH EXOSOMICS S.P.A. FOR THE ESTABLISHMENT OF LONGEVITY BIOSCIENCE SRL
JOINT VENTURE AGREEMENT SIGNED WITH EXOSOMICS S.P.A. FOR THE ESTABLISHMENT OF LONGEVITY BIOSCIENCE SRLTURNOVER FOR THE FIRST HALF OF 2024 EQUAL TO 2.3 MILLION EUROS, AN INCREASE COMPARED TO THE SAME PERIOD IN 2023
TURNOVER FOR THE FIRST HALF OF 2024 EQUAL TO 2.3 MILLION EUROS, AN INCREASE COMPARED TO THE SAME PERIOD IN…SUBSTANTIAL CHANGE IN MATTER OF OWNERSHIP STRUCTURE
SUBSTANTIAL CHANGE IN MATTER OF OWNERSHIP STRUCTURESUBSTANTIAL CHANGE IN MATTER OF OWNERSHIP STRUCTURE
SUBSTANTIAL CHANGE IN MATTER OF OWNERSHIP STRUCTURETURNOVER AS OF 31 MARCH 2024 EQUAL TO 1.1 MILLION EUROS, AN INCREASE OF 26.3% COMPARED TO THE SAME PERIOD IN 2023
TURNOVER AS OF 31 MARCH 2024 EQUAL TO 1.1 MILLION EUROS, AN INCREASE OF 26.3% COMPARED TO THE SAME PERIOD…ORDINARY AND EXTRAORDINARY SHAREHOLDERS’ MEETING OF ARTERRA BIOSCIENCE S.P.A.
ORDINARY AND EXTRAORDINARY SHAREHOLDERS' MEETING OF ARTERRA BIOSCIENCE S.P.A.SECOND CALL OF SHAREHOLDERS’ MEETING